p53 Codon 72 Polymorphism Predicts the Pathologic Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Clinical Cancer Research

• Publication date

  2005-10-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-05-0507PMID 16243804
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Evidence-Based Use of Neoadjuvant Taxane in Operable and Inoperable Breast Cancer

  2004cited by this paper
• p53 polymorphic variants at codon 72 exert different effects on cell cycle progression

  2004cited by this paper
• Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo

  2004cited by this paper
• TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer.

  2003cited by this paper
• Correlation between HER‐2 expression and response to neoadjuvant chemotherapy with 5‐fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma

  2003cited by this paper
• The codon 72 polymorphic variants of p53 have markedly different apoptotic potential

  2003cited by this paper
• The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas.

  2002cited by this paper
• Assessing TP53 status in human tumours to evaluate clinical outcome

  2001cited by this paper
• Prognostic value of TP53 gene mutation in adjuvant treated breast cancer patients

  2001cited by this paper
• TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients.

  2000cited by this paper
• HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer.

  2000cited by this paper
• TP 53 Mutation and p 53 Overexpression for Prediction of Response to Neoadjuvant Treatment in Breast Cancer Patients 1

  2000cited by this paper
• The SYT-SSX1 variant of synovial sarcoma is associated with a high rate of tumor cell proliferation and poor clinical outcome.

  1999cited by this paper
• Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis

  1999cited by this paper
• Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.

  1999influential reference
• erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer.

  1998cited by this paper
• Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.

  1998cited by this paper
• Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute.

  1998cited by this paper
• p53 codon 72 polymorphism and risk of cervical cancer in UK.

  1998cited by this paper
• Role of a p53 polymorphism in the development of human papilloma-virus-associated cancer

  1998cited by this paper
• No significant predictive value of c‐ erbB‐2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer

  1998cited by this paper
• Preoperative chemotherapy induces apoptosis in early breast cancer.

  1997cited by this paper
• Detection of p53 gene mutation by rapid PCR‐SSCP and its association with poor survival in breast cancer

  1997cited by this paper
• Apoptosis. Its significance in cancer and cancer Therapy

  1994cited by this paper

• The multifunctional proline-rich domain of p53 tumor suppressor.

  2025cites this paper
• TP53 Gene Polymorphism at Codon 72 as a Response Predictor for Neoadjuvant Chemotherapy

  2024cites this paper
• Potential role of genetic polymorphisms in neoadjuvant chemotherapy response in breast cancer

  2024cites this paper
• Racial Disparity in Anthracycline-induced Cardiotoxicity in Breast Cancer Patients

  2023cites this paper
• Targeting PSAT1 to mitigate metastasis in tumors with p53-72Pro variant

  2023cites this paper
• Low prevalence of germline TP53 and PALB2 mutations in unselected cohort of breast cancer patients from Brunei Darussalam

  2023cites this paper
• Targeted Sequencing of Germline Breast Cancer Susceptibility Genes for Discovering Pathogenic/Likely Pathogenic Variants in the Jakarta Population

  2022cites this paper
• The genotypes and phenotypes of missense mutations in the proline domain of the p53 protein

  2022cites this paper
• Genetic associations of TP53 codon Pro72Arg polymorphism (rs1042522) in coronary artery disease: A meta-analysis of candidate genetic mutants

  2021cites this paper
• Single nucleotide polymorphisms as the efficient prognostic markers in breast cancer.

  2021cites this paper
• Targeted next generation sequencing identifies somatic mutations in a cohort of Egyptian breast cancer patients

  2020cites this paper
• Linkage disequilibrium and haplotypes of five TP53 polymorphisms in oesophageal cancer patients

  2020cites this paper
• Clonal Evolution of TP53 c.375+1G>A Mutation in Pre- and Post- Neo-Adjuvant Chemotherapy (NACT) Tumor Samples in High-Grade Serous Ovarian Cancer (HGSOC)

  2019cites this paper
• TP53 single nucleotide polymorphism (rs1042522) in Iranian patients with coronary artery disease.

  2018cites this paper
• A single-nucleotide polymorphism of the beta 2-adrenergic receptor gene can predict pathological complete response to taxane- and platinum-based neoadjuvant chemotherapy in breast cancer

  2018cites this paper
• The 72Pro Variant of the Tumor Protein 53 Is Associated with an Increased Breast Cancer Risk in the Moroccan Population

  2018cites this paper
• TP53 Arg72Pro polymorphism is associated with increased overall survival but not response to therapy in Portuguese/Caucasian patients with advanced cervical cancer.

  2018cites this paper
• TP53 codon 72 polymorphism and breast cancer risk in Bangladeshi population

  2017cites this paper
• The p53 R72P polymorphism does not affect the physiological response to ionizing radiation in a mouse model

  2017cites this paper
• Effect of p53 Codon 72 Polymorphism on Clinical Outcome in Locally Advanced Breast Cancer Patients Receiving Anthracycline Based Neoadjuvant Chemotherapy

  2017cites this paper
• Clinical significance of TP53 (R72P) and MDM2 (T309G) polymorphisms in breast cancer patients

  2016cites this paper
• USING MOUSE MODELS TO DEFINE HOW THE P53 R72P POLYMORPHISM IMPACTS THE ADVERSE EFFECTS OF DOXORUBICIN AND IONIZING RADIATION

  2016cites this paper
• Single-Nucleotide Polymorphisms and Cancer Risk, Tumor Recurrence, or Survival of Head and Neck Cancer Patients

  2016cites this paper
• Effect of p53 codon 72 polymorphism on the survival outcome in advanced stage cervical cancer patients in India

  2016cites this paper
• Role of p53 Codon72 SNP in breast cancer risk and anthracycline resistance.

  2015cites this paper
• Association between p53 codon 72 polymorphism and curative ef- fect of postoperative chemo-radiotherapy for breast cancer

  2015cites this paper
• Exploratory analysis of candidate germline gene polymorphisms in breast cancer patients treated with neoadjuvant anthracycline-containing chemotherapy and associations with febrile neutropenia.

  2015cites this paper
• Association of Two Polymorphic Codons in P53 and ABCC1 Promoter with Prostate Cancer.

  2015cites this paper
• Genotype and Haplotype Analyses of TP53 Gene in Breast Cancer Patients: Association with Risk and Clinical Outcomes

  2015cites this paper
• A Compensatory Role of NF-κB to p53 in Response to 5-FU–Based Chemotherapy for Gastric Cancer Cell Lines

  2014cites this paper
• TP53 polymorphisms in sporadic North Indian breast cancer patients.

  2014cites this paper
• Analysis of TP53 polymorphisms in North Indian sporadic esophageal cancer patients.

  2014cites this paper
• Analysis of TP 53 Polymorphisms in North Indian Sporadic Esophageal Cancer Patients

  2014cites this paper
• Allele Frequency Of P53 Gene Arg72Pro In Sudanese Meningioma Patients And Controls

  2014cites this paper
• TP53 Pro72 Allele Is Enriched in Oral Tongue Cancer and Frequently Mutated in Esophageal Cancer in India

  2014cites this paper
• TP 53 Polymorphisms in Sporadic North Indian Breast Cancer Patients

  2014cites this paper
• Association of the p53 codon 72 polymorphism with clinicopathological characteristics of colorectal cancer through mRNA analysis.

  2014cites this paper
• The combined effects of single-nucleotide polymorphisms, tobacco products, and ethanol on normal resting blood mononuclear cells.

  2013cites this paper
• Effect of TP53 codon 72 and MDM2 SNP309 polymorphisms on survival of gastric cancer among patients who receiving 5-fluorouracil-based postoperative adjuvant chemotherapy

  2013cites this paper
• The identification and analysis of molecular biomarkers in the p53 tumour suppressor pathway that affect cancer progression in humans

  2013cites this paper
• Epistatic interaction of Arg72Pro TP53 and −710 C/T VEGFR1 polymorphisms in breast cancer: predisposition and survival

  2013cites this paper
• p53 codon 72 polymorphism in Taiwanese breast cancer patients

  2013cites this paper
• Predictive and prognostic factors in locally advanced breast cancer: effect of intratumoral FOXP3+ Tregs

  2013cites this paper
• p.R72P, PIN3 Ins16bp polymorphisms of TP53 and CCR5?32 in north Indian breast cancer patients.

  2012influential citation
• The p53 codon 72 Pro/Pro genotype identifies poor-prognosis neuroblastoma patients: correlation with reduced apoptosis and enhanced senescence by the p53-72P isoform.

  2012cites this paper
• The Pro Allele of the p53 Codon 72 Polymorphism Is Associated with Decreased Intratumoral Expression of BAX and p21, and Increased Breast Cancer Risk

  2012cites this paper
• Novel genetic markers of breast cancer survival identified by a genome-wide association study.

  2012cites this paper
• Analysis of functional germline polymorphisms for prediction of response to anthracycline-based neoadjuvant chemotherapy in breast cancer

  2012influential citation
• Mutations and polymorphisms in TP53 gene--an overview on the role in colorectal cancer.

  2012cites this paper
• MDM2 SNP309 and TP53 R72P associated with severe and febrile neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide

  2012cites this paper
• The p 53 Codon 72 Pro / Pro Genotype Identifies Poor-Prognosis Neuroblastoma Patients : Correlation with Reduced Apoptosis and Enhanced Senescence by the p 53-72 P Isoform 1 , 2

  2012cites this paper
• Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine

  2012cites this paper
• CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer

  2012cites this paper
• [Predictive factors of response to anthracyclines neoadjuvant chemotherapy in breast cancer].

  2011cites this paper
• The effect of TP53 codon 72 and RNASEL codon 462 polymorphisms on the development of cervical cancer in Argentine women.

  2011cites this paper
• Chimiothérapie néoadjuvante par anthracyclines dans le cancer du sein : facteurs prédictifs de réponse

  2011cites this paper
• TP53 Status and Response to Treatment in Breast Cancers

  2011cites this paper
• The TP53 gene polymorphisms and survival of sporadic breast cancer patients

  2011cites this paper
• Avaliação da superexpressão da proteína p53 e das mutações no éxon 8 do gene TP53 em carcinomas mamários caninos e glândulas normais

  2011cites this paper
• P53 gene polymorphisms and breast cancer risk in Arab women

  2011cites this paper
• Genetic variations of DNA repair genes and their prognostic significance in patients with acute myeloid leukemia

  2011cites this paper
• Role of p53 and p21 polymorphisms in the risk of cervical cancer among Chinese women.

  2010cites this paper
• R72P Polymorphism of TP53 in Ulcerative Colitis Patients is Associated with the Incidence of Colectomy, Use of Steroids and the Presence of a Positive Family History

  2010cites this paper
• Distribution of TYMS, MTHFR, p53 and MDR1 gene polymorphisms in patients with breast cancer treated with neoadjuvant chemotherapy.

  2010influential citation
• TYMS, MTHFR, p53 and MDR1 gene polymorphisms in breast cancer patients treated with adjuvant therapy.

  2010cites this paper
• FGFR 4 Arg 388 genotype is associated with pathological complete response to neoadjuvant chemotherapy for primary breast cancer

  2010cites this paper
• FGFR4 Arg388 genotype is associated with pathological complete response to neoadjuvant chemotherapy for primary breast cancer.

  2010cites this paper
• Potential Increase in the Prognostic Value of p53 Mutation by Pro72 Allele in Stage I Non-Small-Cell Lung Cancer

  2009cites this paper
• Gene polymorphisms in TYMS, MTHFR, p53 and MDR1 as risk factors for breast cancer: a case-control study.

  2009cites this paper
• p53 polymorphisms: cancer implications

  2009cites this paper
• Polymorphisms of TP53 codon 72 with breast carcinoma risk: evidence from 12226 cases and 10782 controls

  2009cites this paper
• Association of TP53 and MDM2 polymorphisms with survival in bladder cancer patients treated with chemoradiotherapy

  2009cites this paper
• Resistance to Chemotherapy in Breast Cancer: Potential role of p21B, p27 and the p53 apoptotic pathway

  2009cites this paper
• p53 Arg72Pro and MDM2 T309G Polymorphisms, Histology, and Esophageal Cancer Prognosis

  2009cites this paper
• Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients

  2009cites this paper
• Biological significance of allele specific loss of the p53 gene in breast carcinomas

  2009cites this paper
• Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin

  2009cites this paper
• Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy

  2009cites this paper
• TP53 Codon 72 Polymorphism in Classic, Endemic and Epidemic Kaposi’s Sarcoma in African and Caucasian Patients

  2009cites this paper
• The effect of genetic variability on drug response in conventional breast cancer treatment.

  2009cites this paper
• TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin

  2009cites this paper
• Combination of p53 codon 72 polymorphism and inactive p53 mutation predicts chemosensitivity to 5‐fluorouracil in colorectal cancer

  2009cites this paper
• The significance of minimally invasive core needle biopsy and immunohistochemistry analysis in 235 cases with breast lesions

  2009cites this paper
• K-Ras Mutations and Treatment Outcome in Colorectal Cancer Patients Receiving Exclusive Fluoropyrimidine Therapy

  2008cites this paper
• K-RasMutations and Treatment Outcome in Colorectal Cancer Patients Receiving Exclusive FluoropyrimidineTherapy

  2008cites this paper
• ATM, RAD50 and p53 in breast cancer

  2008cites this paper
• Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder.

  2008cites this paper
• Role of p53 Codon 72 Arginine Allele in Cell Survival in vitro and in the Clinical Outcome of Patients with Advanced Breast Cancer

  2008cites this paper
• P53Arg72 homozygosity and its increased incidence in left-sided sporadic colorectal adenocarcinomas, in a Greek-Caucasian population.

  2008cites this paper
• Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer

  2008cites this paper
• Polymorphisms in p53 and the p53 pathway: roles in cancer susceptibility and response to treatment

  2008cites this paper
• Importance of TP53 codon 72 and intron 3 duplication 16bp polymorphisms in prediction of susceptibility on breast cancer

  2008cites this paper
• TP53 codon 72 polymorphism in susceptibility, overall survival, and adjuvant therapy response of gliomas.

  2008cites this paper
• TP53 Status and Response to Chemotherapy in Breast Cancer

  2008cites this paper
• Prognostic role of p53 codon 72 polymorphism in gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy

  2008cites this paper
• Effect of p53 codon 72 genotype on breast cancer survival depends on p53 gene status

  2008cites this paper
• Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients

  2007influential citation
• Association of p53 polymorphisms with breast cancer: a case-control study in Slovak population.

  2007cites this paper
• p53, BRCA1 and breast Cancer chemoresistance.

  2007cites this paper
• Using specific cytotoxics with a targeted mind.

  2007cites this paper